The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections.

IF 3.6 3区医学 Q2 INFECTIOUS DISEASES Current Opinion in Infectious Diseases Pub Date : 2024-08-14 DOI:10.1097/qco.0000000000001059

Matteo Bassetti,Daniele Roberto Giacobbe,Nadia Castaldo,Antonio Vena

{"title":"The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections.","authors":"Matteo Bassetti,Daniele Roberto Giacobbe,Nadia Castaldo,Antonio Vena","doi":"10.1097/qco.0000000000001059","DOIUrl":null,"url":null,"abstract":"PURPOSE OF REVIEW\r\nInfections caused by multidrug-resistant Acinetobacter baumannii present a significant global health challenge. Available treatment options are limited and frequently constrained by unfavourable safety and pharmacokinetic profiles. Sulbactam-durlobactam is a novel β-lactamase inhibitors combination specifically developed to target A. baumannii, including carbapenem-resistant strains. The purpose of this review is to assess the current evidence supporting the role of sulbactam-durlobactam in the management of A. baumannii infections.\r\n\r\nRECENT FINDINGS\r\nWe summarize the available evidence regarding the pharmacokinetic and pharmacodynamic profiles of sulbactam-durlobactam from key in-vitro and in-vivo studies. Additionally, efficacy results from the Phase III randomized controlled trial and real-world data on sulbactam-durlobactam's use against severe A. baumannii infections are also discussed.\r\n\r\nSUMMARY\r\nSulbactam-durlobactam is a promising addition to the treatment options for carbapenem-resistant A. baumannii infections. Ongoing research and vigilance are essential to monitor the development of in-vivo resistance, assess effectiveness across diverse patient populations, and explore potential synergistic combinations with other antimicrobials. Careful stewardship and comprehensive clinician education will be crucial to optimizing the clinical use of sulbactam-durlobactam.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/qco.0000000000001059","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

PURPOSE OF REVIEW Infections caused by multidrug-resistant Acinetobacter baumannii present a significant global health challenge. Available treatment options are limited and frequently constrained by unfavourable safety and pharmacokinetic profiles. Sulbactam-durlobactam is a novel β-lactamase inhibitors combination specifically developed to target A. baumannii, including carbapenem-resistant strains. The purpose of this review is to assess the current evidence supporting the role of sulbactam-durlobactam in the management of A. baumannii infections. RECENT FINDINGS We summarize the available evidence regarding the pharmacokinetic and pharmacodynamic profiles of sulbactam-durlobactam from key in-vitro and in-vivo studies. Additionally, efficacy results from the Phase III randomized controlled trial and real-world data on sulbactam-durlobactam's use against severe A. baumannii infections are also discussed. SUMMARY Sulbactam-durlobactam is a promising addition to the treatment options for carbapenem-resistant A. baumannii infections. Ongoing research and vigilance are essential to monitor the development of in-vivo resistance, assess effectiveness across diverse patient populations, and explore potential synergistic combinations with other antimicrobials. Careful stewardship and comprehensive clinician education will be crucial to optimizing the clinical use of sulbactam-durlobactam.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

舒巴坦-杜鲁巴坦在治疗耐碳青霉烯类杆菌感染中的作用。

耐多药鲍曼不动杆菌引起的感染是全球健康面临的重大挑战。现有的治疗方案十分有限，而且经常受到安全性和药代动力学特征不佳的限制。舒巴坦-杜鲁巴坦是一种新型β-内酰胺酶抑制剂复方制剂，专门针对鲍曼不动杆菌（包括耐碳青霉烯菌株）开发。本综述旨在评估支持舒巴坦-杜鲁巴坦在治疗鲍曼尼氏菌感染中发挥作用的现有证据。我们总结了主要体外和体内研究中有关舒巴坦-杜鲁巴坦药代动力学和药效学特征的现有证据。此外，还讨论了 III 期随机对照试验的疗效结果以及舒巴坦-杜鲁巴坦用于治疗严重鲍曼不动杆菌感染的实际数据。持续的研究和警惕对于监测体内耐药性的发展、评估不同患者群体的疗效以及探索与其他抗菌药物的潜在协同组合至关重要。谨慎管理和全面的临床医生教育对于优化舒巴坦-杜鲁巴坦的临床应用至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Opinion in Infectious Diseases 医学-传染病学

CiteScore

6.70

自引率

2.60%

发文量

121

审稿时长

6-12 weeks

期刊介绍： This reader-friendly, bimonthly resource provides a powerful, broad-based perspective on the most important advances from throughout the world literature. Featuring renowned guest editors and focusing exclusively on two topics, every issue of Current Opinion in Infectious Disease delivers unvarnished, expert assessments of developments from the previous year. Insightful editorials and on-the-mark invited reviews cover key subjects such as HIV infection and AIDS; skin and soft tissue infections; respiratory infections; paediatric and neonatal infections; gastrointestinal infections; tropical and travel-associated diseases; and antimicrobial agents.